New cancer clinical trial: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Published on: May 30, 2018 at 12:00PM
Condition:   Advanced Kidney Cancer
Interventions:   Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer;   Procedure: cryotherapy
Sponsors:   Fuda Cancer Hospital, Guangzhou;   Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Recruiting
https://ift.tt/2LbsT8p